Tolerogenics technology explained

Tolerogenics therapy approach for the treatment of immune diseases is based on the effective induction of tolerance. In a simplified view, immune diseases like allergy or autoimmune diseases can be seen as an imbalance of the immune system towards harmful acting effector T cells (Teffs). One of Tolerogenics patent-protected enabling technologies to achieve the induction of tolerance is the thermosensitive ImmuneGel technology. The proprietary hydrogel composition can be injected subcutaneously and forms a drug depot for sustained local release of active substances in effective concentrations.

Diffusion-based released “find-me” signals from the hydrogel attract antigen-presenting cells (APC, PhagoAttract technology) for efficient immune cell modulation. Peptide-loaded tolerizing PS-liposomes (ToleroAIT technology) are sustainly released from the hydrogel over time. Attracted APC will take up the PS-liposomes by phagocytosis and are turned into tolerogenic allergen/autoantigen-specific APC. These primed tolerogenic APC will interact with T cells and induce the generation of allergen/autoantigen-specific regulatory T cells (Tregs). The induced Tregs will migrate and suppress the harmful activity of Teffs in the body and reinstate a healthy immune balance.